Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TREZIX vs SEDAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Capsaicin is a TRPV1 receptor agonist that initially causes pain and neuropeptide release, followed by desensitization and depletion of substance P from sensory nerve terminals, reducing pain transmission. Hydrocodone is a mu-opioid receptor agonist, modulating pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, reducing prostaglandin synthesis and pain signaling.
SEDAPAP is a combination of an opioid agonist (acetaminophen, hydrocodone) and a non-opioid analgesic. Hydrocodone acts as a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and providing analgesia and antipyresis.
FDA-approved: Management of moderate to moderately severe pain where treatment with an opioid is appropriate,Off-label: Chronic pain syndromes, neuropathic pain
Management of moderate to moderately severe pain where an opioid analgesic is required
TREZIX (acetaminophen 320 mg, dichloralphenazone 100 mg, isometheptene mucate 65 mg) capsules: 2 capsules orally at onset of headache, then 1 capsule every hour until relief (maximum 5 capsules in 12 hours, 10 capsules in 24 hours). For migraine: 2 capsules orally at onset, then 1 capsule every hour as needed (maximum 5 capsules per attack).
1-2 tablets (acetaminophen 325 mg/butalbital 50 mg/caffeine 40 mg) orally every 4 hours as needed; maximum 6 tablets per day.
Terminal elimination half-life is approximately 2.5-3.5 hours for the parent compound; clinically, this necessitates dosing every 4-6 hours for sustained effect during wakefulness, but accumulation is minimal with normal hepatic and renal function.
The terminal elimination half-life is approximately 4-6 hours in adults with normal renal function. In patients with creatinine clearance <30 m L/min, the half-life may be prolonged to 10-15 hours, requiring dose adjustment.
Hydrocodone: Hepatic metabolism via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone, respectively. Acetaminophen: Conjugation primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1), with minor CYP2E1 oxidation to NAPQI.
Hydrocodone is metabolized primarily via CYP3A4 and CYP2D6 to hydromorphone and other metabolites. Acetaminophen is metabolized primarily via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a hepatotoxic metabolite (NAPQI) that is normally detoxified by glutathione.
Renal excretion of metabolites (primarily as glucuronide conjugates and unchanged drug) accounts for approximately 55-65% of the dose; biliary/fecal elimination accounts for approximately 25-35%.
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose. Hepatic metabolism to inactive metabolites, followed by biliary and fecal elimination, accounts for the remaining 30-40%. Less than 5% is excreted unchanged in feces.
Approximately 35-40% bound to plasma proteins, primarily albumin.
Approximately 92-95% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein.
Volume of distribution is approximately 3-4 L/kg, indicating extensive tissue distribution with penetration into the central nervous system.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive distribution into total body water and tissues. Higher Vd is observed in obesity (up to 1.5 L/kg).
Oral bioavailability is approximately 50-70% due to first-pass hepatic metabolism.
Oral: 75-85% due to first-pass metabolism. Intramuscular: 90-100%. Intravenous: 100%.
No specific GFR-based dose adjustments available; contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to acetaminophen and dichloralphenazone accumulation. Use with caution in moderate impairment (Cr Cl 30-60 m L/min); consider extending dosing interval to every 6-8 hours.
GFR 30-50 m L/min: Use with caution, maximum 4 tablets per day. GFR <30 m L/min: Contraindicated due to butalbital accumulation.
Contraindicated in Child-Pugh class C (severe hepatic impairment). In Child-Pugh class A or B: reduce dose by 50% and monitor liver function; maximum acetaminophen daily dose should not exceed 2000 mg. Avoid in active liver disease.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%, maximum 3 tablets per day. Child-Pugh C: Contraindicated.
Not recommended for children under 12 years due to lack of safety data. For adolescents 12-17 years: 1-2 capsules orally at onset, then 1 capsule every hour as needed (maximum 3 capsules in 12 hours). Weight-based dosing not established.
Not recommended for patients under 12 years of age.
Initiate with lower dose (1 capsule at onset) and monitor closely due to increased sensitivity to anticholinergic effects of dichloralphenazone. Maximum daily acetaminophen dose not to exceed 3000 mg. May require longer dosing intervals (every 6-8 hours).
Initiate at lowest effective dose (1 tablet every 6 hours); monitor for excessive sedation and cognitive impairment.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; HEPATOTOXICITY (due to acetaminophen); RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Addiction, Abuse, and Misuse: SEDAPAP exposes users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and monitor regularly. Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially during initiation and dose titration. Accidental Ingestion: Accidental ingestion of even one dose, especially by children, can cause fatal overdose. Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening. Cytochrome P450 3A4 Interaction: Concomitant use with CYP3A4 inhibitors may increase hydrocodone levels and prolong adverse effects. Concomitant use with CYP3A4 inducers may decrease efficacy. Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants: Concomitant use may result in profound sedation, respiratory depression, coma, and death. Avoid use in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks with CYP3A4 inhibitors or discontinuation; hepatotoxicity from acetaminophen overdose; hypersensitivity reactions; severe hypotension; gastrointestinal obstruction; seizures; serotonin syndrome with concomitant serotonergic drugs; impaired mental/physical abilities; adrenal insufficiency; androgen deficiency.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; adrenal insufficiency; hepatotoxicity (due to acetaminophen); opioid-induced hyperalgesia; withdrawal; risks of use in patients with head injuries, impaired consciousness, or increased intracranial pressure; use in patients with gastrointestinal conditions including paralytic ileus; use in patients with severe renal or hepatic impairment; use in elderly, cachectic, or debilitated patients; use in patients with pulmonary disease; use in patients with biliary tract disease; use in patients with acute pancreatitis; use in patients with CNS depression; use in patients with toxic psychosis; use in patients with known or suspected surgical abdomen; use in patients with urinary retention; use in patients with prostatic hypertrophy; use in patients with urethral stricture; use in patients with hypothyroidism; use in patients with Addison's disease; use in patients with kyphoscoliosis; use in patients with severe obesity; use in patients with seizures or seizure disorders; use in patients with substance abuse history; driving and operating machinery; use in pregnancy; use in lactation.
Hypersensitivity to any ingredient; significant respiratory depression; acute or severe bronchial asthma in unmonitored settings; known or suspected gastrointestinal obstruction; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (due to acetaminophen).
Hypersensitivity to hydrocodone, acetaminophen, or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Avoid alcohol. Limit caffeine from other sources (coffee, tea, soda) to prevent excessive stimulation. High-fat meals may delay absorption but do not significantly alter overall effect.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. High-fat meals may delay absorption but not clinically significant. No specific food restrictions.
TREZIX (acetaminophen, dichloralphenazone, isometheptene) is contraindicated in pregnancy. First trimester: risk of neural tube defects and other malformations due to acetaminophen? limited data but dichloralphenazone is a barbiturate derivative with known teratogenicity (cleft palate, cardiac defects). Second and third trimesters: barbiturates may cause neonatal dependence, withdrawal, and bleeding disorders (vitamin K deficiency). Late third trimester: maternal use of barbiturates may lead to neonatal respiratory depression and withdrawal. Avoid in all trimesters.
First trimester: Increased risk of neural tube defects and orofacial clefts (valproate component). Second and third trimesters: Fetal valproate syndrome (craniofacial abnormalities, cardiac defects, developmental delay), neonatal hemorrhage due to vitamin K deficiency (valproate), and withdrawal syndrome. Acetaminophen carries minimal risk.
No specific studies for TREZIX. Acetaminophen is compatible with breastfeeding (M/P ratio ~1.0). Dichloralphenazone (metabolized to trichloroethanol) and isometheptene: data lacking. Barbiturate metabolites may cause infant sedation, poor feeding, and withdrawal risk. Manufacturer advises caution; use alternative if possible.
Both valproate and acetaminophen are excreted into breast milk. Valproate M/P ratio approximately 0.05-0.1; infant serum levels low but potential for hepatotoxicity and thrombocytopenia. Acetaminophen M/P ratio ~1.0, considered safe in therapeutic doses. Caution advised with valproate; monitor infant for jaundice, bruising, and sedation.
Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism, renal clearance) may reduce drug levels. However, TREZIX is contraindicated due to teratogenicity and maternal/fetal risks; therefore, no dosing adjustment is recommended. Alternative therapy should be used.
Valproate: Dose may need reduction due to increased clearance (plasma levels decrease 30-50% in late pregnancy); monitor serum levels and adjust to maintain therapeutic concentration. Acetaminophen: No dose adjustment required in pregnancy; standard dosing recommended.
TREZIX (acetaminophen, caffeine, and dihydrocodeine) is a fixed-dose combination analgesic with abuse potential; monitor for opioid-induced constipation and respiratory depression. Avoid exceeding 4 grams/day of acetaminophen due to hepatotoxicity risk. Caffeine may potentiate analgesic effects but can cause insomnia and anxiety. Discontinue prior to surgery to avoid withdrawal and respiratory complications.
SEDAPAP is a combination product containing an opioid (codeine or hydrocodone) and acetaminophen. Avoid exceeding 3 grams/day of acetaminophen to prevent hepatotoxicity. Monitor respiratory depression, especially in opioid-naive patients and those with sleep apnea. Use with caution in hepatic impairment, ethanol use disorder, and in patients on other CNS depressants. Administer with food to reduce GI upset.
Take exactly as prescribed; do not increase dose or frequency without doctor approval.,Do not combine with other acetaminophen-containing products to avoid liver damage.,Avoid alcohol while taking this medication.,Do not drive or operate heavy machinery until you know how TREZIX affects you.,Report severe constipation, difficulty breathing, or signs of allergic reaction immediately.,Do not stop suddenly; taper under medical supervision to prevent withdrawal.
Do not exceed recommended dose; too much acetaminophen can cause liver damage.,Avoid alcohol while taking this medication.,Do not combine with other acetaminophen-containing products.,May cause drowsiness or dizziness; avoid driving or operating machinery.,Take with food or milk if stomach upset occurs.,Report any difficulty breathing, severe constipation, or signs of liver injury (yellowing skin/eyes, dark urine) immediately.,Do not stop suddenly after prolonged use to avoid withdrawal symptoms.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TREZIX vs SEDAPAP, answered by our medical review team.
TREZIX is a Barbiturate Combination Analgesic that works by Capsaicin is a TRPV1 receptor agonist that initially causes pain and neuropeptide release, followed by desensitization and depletion of substance P from sensory nerve terminals, reducing pain transmission. Hydrocodone is a mu-opioid receptor agonist, modulating pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, reducing prostaglandin synthesis and pain signaling.. SEDAPAP is a Barbiturate Combination Analgesic that works by SEDAPAP is a combination of an opioid agonist (acetaminophen, hydrocodone) and a non-opioid analgesic. Hydrocodone acts as a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and providing analgesia and antipyresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TREZIX and SEDAPAP depend on the specific clinical indication. These are both Barbiturate Combination Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TREZIX is: TREZIX (acetaminophen 320 mg, dichloralphenazone 100 mg, isometheptene mucate 65 mg) capsules: 2 capsules orally at onset of headache, then 1 capsule every hour until relief (maximum 5 capsules in 12 hours, 10 capsules in 24 hours). For migraine: 2 capsules orally at onset, then 1 capsule every hour as needed (maximum 5 capsules per attack).. The standard adult dose of SEDAPAP is: 1-2 tablets (acetaminophen 325 mg/butalbital 50 mg/caffeine 40 mg) orally every 4 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TREZIX and SEDAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TREZIX is classified as Category C. TREZIX (acetaminophen, dichloralphenazone, isometheptene) is contraindicated in pregnancy. First trimester: risk of neural tube defects and other malformations due to acetaminophen. SEDAPAP is classified as Category C. First trimester: Increased risk of neural tube defects and orofacial clefts (valproate component). Second and third trimesters: Fetal valproate syndrome (craniofacial abnormalities. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.